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Abstract
The genus Cyclopia, an indigenous South African fynbos plant used to prepare honeybush
tea, contains phytoestrogenic compounds. An extract from C. subternata, SM6Met, displays
three desirable estrogenic attributes for future development of a phytoestrogenic nutraceuti-
cal, namely, ERα antagonism, ERβ agonism, and also antagonism of E2-induced breast
cancer cell proliferation. Activity-guided fractionation of SM6Met was used in an attempt to
isolate and identify compounds conferring the desirable estrogenic profile to SM6Met. Initial
liquid-liquid fractionation of SM6Met yielded a polar fraction (PF) and a non-polar fraction
(NPF), with the desirable estrogenic attributes retained in the NPF. Subsequent high perfor-
mance counter-current chromatography (HPCCC) fractionation of the NPF yielded three
fractions (F1-F3). Interestingly, the fractions revealed separation of the previously demon-
strated positive estrogenic attributes of the NPF into separate fractions, with F1 and F2 act-
ing as ERα antagonists, only F2 inducing antagonism of E2-induced breast cancer cell
proliferation and only F3 retaining robust ERβ agonist activity. In terms of major polyphe-
nols, quantitative HPLC and liquid chromatography tandem mass spectrometry (LC-MS/
MS) indicated that HPCCC fractionation resulted in a divergence of polyphenolic classes,
with F1 emerging as the dihydrochalcone-rich fraction and F2 as the flavanone- and benzo-
phenone-rich fraction, while the xanthones, flavones and phenolic acids were retained in
F3. F3 was re-engineered into F3R by reassembling the major polyphenols identified in the
fraction. F3R could, however, not replicate the effect of F3. In conclusion, although activity-
guided fractionation results suggest that retention of all the desirable estrogenic attributes
of the original SM6Met in one fraction is not an attainable goal, fractionation is a useful tool
to enhance specific desirable estrogenic attributes.
PLOS ONE | DOI:10.1371/journal.pone.0132950 July 24, 2015 1 / 22
a11111
OPEN ACCESS
Citation: Mortimer M, Visser K, de Beer D, Joubert
E, Louw A (2015) Divide and Conquer May Not Be
the Optimal Approach to Retain the Desirable
Estrogenic Attributes of the Cyclopia Nutraceutical
Extract, SM6Met. PLoS ONE 10(7): e0132950.
doi:10.1371/journal.pone.0132950
Editor: Arun Rishi, Wayne State University, UNITED
STATES
Received: May 8, 2015
Accepted: June 20, 2015
Published: July 24, 2015
Copyright: © 2015 Mortimer et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors would like to thank the
Medical Research Council (http://www.mrc.ac.za/)
and the Cancer Association of South Africa (http://
www.cansa.org.za/) for financial support to AL (grant
for projects entitled “Cyclopia Phytoestrogens” and
“Cyclopia and breast cancer”) and for financial
support to KV and MM the National Research




Nutraceuticals, i.e. food extract supplements with health benefits [1], have become a multi-bil-
lion dollar global industry [2]. Consumers have shown renewed interest in nutraceuticals as a
consequence of increased public health consciousness [3], increasing costs of modern medi-
cines [4], and increasing concerns regarding side effects associated with conventional therapies
[5,6]. Africa is currently not seen as a competitive market for nutraceuticals, however, an
emerging market is establishing itself in South Africa [7,8], thus opening the door for the devel-
opment of a uniquely South African nutraceutical.
Cyclopia species (family Fabaceae) are endemic to theWestern and Eastern Cape Provinces of
South Africa [9], and have been harvested for more than a century for the production of an
herbal tea known as honeybush tea, produced from ‘fermented’ (oxidized) plant material [10].
Renewed interest in Cyclopia in the 1990’s led to the production of green or ‘unfermented’ hon-
eybush tea, in order to prevent breakdown of potentially health-promoting polyphenols during
the high temperature oxidation process. This ‘unfermented’ plant material could serve as a source
for nutraceutical extracts [11]. As consumers worldwide demonstrated an increased demand for
health-promoting foods, the honeybush industry has benefitted through a growing export market
[9]. Several in vitro and in vivo studies have already shown that several Cyclopia species have anti-
mutagenic [12], antioxidant [13], anticancer [14–16] and also phytoestrogenic properties [10].
Women undergoing the menopausal transition have shown great interest in phytoestro-
genic nutraceuticals as an alternative to conventional hormone replacement therapy (HRT)
due to the disquieting side-effect profile of HRT [17–21], with breast cancer as a primary
adverse outcome [19,20]. Studies have shown that phytoestrogen consumption cannot only
alleviate menopausal symptoms, but may also lower the incidence of osteoporosis, cardiovascu-
lar disease, and hormone dependent cancers, such as breast cancer [22–28].
The possibility of Cyclopia as a phytoestrogen source was first raised in two studies by Ver-
hoog et al. [29,30]. In the initial study [29] it was found that extracts from both C. genistoides
and C. subternata displayed phytoestrogenic activity, and that optimal estrogenicity was gener-
ated by using methanol extracts, as opposed to aqueous extracts, from unfermented plant mate-
rial. In the second study [30] a dried methanol extract (DME) of C. genistoides, P104, was shown
to bind to both estrogen receptor (ER) subtypes, transactivate an estrogen response element
(ERE) containing promoter reporter construct only via ERβ, and also antagonize 17β-estradiol
(E2)-induced breast cancer cell proliferation. Subsequent screening of extracts produced from C.
genistoides and C. subternata [31], resulted in the identification of SM6Met, a sequential metha-
nol extract of a C. subternata harvesting, M6. SM6Met was estrogenically the most potent of the
screened Cyclopia extracts, with potency comparable to commercially available phytoestrogenic
nutraceuticals [31]. More recently, investigation into the estrogenic specificity of SM6Met
revealed that the extract displays three desirable estrogenic attributes for future development of a
phytoestrogenic nutraceutical, namely, ERα antagonism, ERβ agonism, and also antagonism of
E2-induced breast cancer cellular proliferation [32]. This suggests that SM6Met contains a com-
pound or compounds conferring subtype specific estrogenic activity [33], which may be benefi-
cial as it has been shown that physiologically, ERα is associated with the stimulation of cell
proliferation and the increased occurrence of breast cancer, while ERβ diminishes the effect of
ERα in breast cancer and could act as an inhibitor of breast cancer development [34–41]. Thus a
phytoestrogenic nutraceutical with the desirable estrogenic attributes displayed by SM6Met may
alleviate menopausal symptoms through ERβ activation, whilst as a positive side effect it might
prevent the development of breast cancer through ERα antagonism [42].
For the future development of a phytoestrogenic nutraceutical, the candidate formulation, as
for any new nutraceutical, should meet important prerequisites for the marketing of health
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claims [43]. One important prerequisite is formulation standardization, which includes efficacy,
quality and safety data, however, equally important prerequisites include identification of the
active compound(s), and elucidation of the molecular mechanism of action, which covers
amongst others absorption, distribution, metabolism and excretion (ADME) of the active com-
pound(s) [44–47]. Identification of the compounds conferring the desirable estrogenic attributes
to SM6Met is not only important for the manufacturing process of a quality-assured phytoestro-
genic nutraceutical [43], but will also be important for screening prospective Cyclopia harvest-
ings destined for nutraceutical production and as marker compound(s) that could in future be
used to direct plant breeding programs of Cyclopia plants for nutraceutical production.
The current study, part of a larger study investigating the development of a phytoestrogenic
nutraceutical from Cyclopia, focuses on activity-guided fractionation of SM6Met from C. subter-
nata to identify the compound(s) responsible for its desirable estrogenic attributes, namely ERβ
agonism, ERα antagonism and antagonism of E2-induced breast cancer cell proliferation [30–
32]. Promoter reporter and breast cancer cell proliferation assays were employed to monitor
estrogenic activity and quantitative HPLC (qHPLC) and LC-MS/MS were used to track poly-
phenols during fractionation for correspondence with positive estrogenic attributes. High per-
formance counter-current chromatography (HPCCC) was selected for fractionation due to the
advantage of complete recovery of the extract in contrast to liquid chromatography using a solid
stationary phase. Finally, we re-engineered [48] the most promising fraction using the major
polyphenols identified and comparing estrogenic activity with that of the original fraction.
Materials and Methods
Compounds
The following compounds were used in cell culture for estrogenic assays: E2 (17β-estradiol)
(Sigma Aldrich), luteolin (Extrasynthese, France), mangiferin (Sigma-Aldrich), isomangiferin
(Chemos GmbH, Germany), protocatechuic acid, p-coumaric acid (Fluka Analytical, Sigma-
Aldrich), scolymoside (Sigma-Aldrich), and iriflophenone-3-C-β-D-glucoside (Sigma-
Aldrich). Phenolic compounds listed above were also used to identify and/or quantify com-
pounds in the extract and fractions, in addition to phloretin-3',5'-di-C-β-D-glucoside (isolated
from C. subternata, unpublished results), eriocitrin (Extrasynthese), hesperidin (Sigma-
Aldrich), vicenin-2 (Phytolab, Germany), isorhoifolin (Extrasynthese), scolymoside (isolated
from C. subternata, unpublished results), and iriflophenone-3-C-β-D-glucoside-4-O-β-D-glu-
coside (isolated from Cyclopia genistoides [49]).
Fractionation of SM6Met
Preparation of SM6Met. The method (S1 Fig), executed at room temperature and
adapted fromMfenyana et al. [31], entailed defatting of 500 g finely milled, dried plant mate-
rial, originating from a Cyclopia subternata harvesting (M6; harvested on 30 March 2004 from
a commercial plantation at Kanetberg farm near Barrydale, South Africa) [31], by stirred
extraction over a period of 24 h, using 2 L of dichloromethane (Merck, South Africa, 99.0%
pure). Following extraction the plant material was filtered, the filtrate discarded, and the plant
material residue air-dried overnight in a fume cabinet at room temperature. This defatting pro-
cess was repeated four times. Next, the air-dried, defatted M6 plant material was subjected to
sequential extraction using three solvents (2 L each) in order of increasing polarity (ethyl ace-
tate (99.5% pure), ethanol (99.5% pure) and methanol (99.0% pure), supplied by Merck). Each
extraction step in the sequence was performed three times for 3 h per step. Before a solvent
change was made, the plant material was air-dried overnight in a fume cabinet at room temper-
ature. The filtrates of the methanol extraction step were retained, pooled, and the methanol
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evaporated under vacuum (Büchi Rotavap, Switzerland) at 40°C, where after a small quantity
of deionized water was added and the extract freeze-dried (Virtis Advantage Plus, USA). The
freeze dried extract was ground with a pestle and mortar until a fine powder was obtained,
which was then stored under vacuum in a desiccator in the dark at room temperature. Four
batches of SM6Met were prepared using the protocol above with the final SM6Met extract (311
g) being a homogenized mixture of the four batches.
Liquid-liquid fractionation. SM6Met (4.3 g), suspended in 300 mL deionized water and
decanted into a separating funnel, was liquid-liquid fractionated (S1 Fig) using 150 mL of n-
butanol (Sigma Aldrich, South Africa). Mixing was achieved by inverting the funnel 5 times
(pressure in the separating funnel was released after every invert), where after the mixture was
allowed to form two layers, and the lower, polar, and the upper, less polar, layers collected sepa-
rately. For the purpose of this study the less polar fraction will be referred to as the non-polar
fraction (NPF). The process was repeated four times. The resultant fractions, the polar fraction
(PF) and the NPF, were pooled and rotary evaporated under vacuum at 40°C. Following freez-
ing and freeze-drying, the dried extracts were stored at room temperature under vacuum in a
desiccator in the dark.
High performance counter-current chromatography (HPCCC) fractionation. Amulti-
layer coil planet J-type centrifuge Spectrum model (Dynamic Extraction, United Kingdom)
equipped with two preparative (1.6 mm i.d.) and two analytical (0.8 mm i.d.) coils of polytetra-
fluoroethylene (PTFE) tubing, connected in series for a total volume of 172 ml, was used. The
inner βr-value for the preparative coil was measured as 0.52 at the internal end of the coil and
the outer βr-value was 0.86 (equation βr = r/R, in this case r is defined as the distance from the
coil (planetary) axis to the nearest and farthest layer of the PTFE tubes wound around the coil
system), while the inner and outer βr-values for the analytical coil were 0.64 and 0.81, respec-
tively. Fractionation was performed at 30°C and rotation speed of 1600 revolutions per min.
The two-phase solvent system used consisted of tert-butyl methyl ether (Sigma Aldrich)–n-
butanol (Sigma Aldrich)–water (2:1:5, v/v). The solvents were mixed in a separating funnel,
allowed to equilibrate at room temperature and separated into the organic and aqueous phases
shortly before use. The separated phases were degassed using sonication. The upper organic phase
served as the stationary phase, whereas the lower aqueous phase served as the mobile phase.
The column was filled with the stationary (organic) phase using a Gilson 305 HPLC pump
(Gilson, USA). The sample (30 mg NPF) was dissolved in 2.5 mL organic phase and 2.5 mL
aqueous phase and then injected into the coil using a manual sample injection valve and a 10
mL loop. The mobile (aqueous) phase was pumped in the head-to-tail direction at a flow rate
of 3 mL/min. The effluent of the column, monitored between 210 nm and 400 nm, using a
Waters 2996 diode-array detector (Waters, USA) equipped with a semi-preparative flow cell (3
mm path length), was collected into test tubes at 1 min intervals, using a Gilson FC203B frac-
tion collector. The mobile phase flow was stopped at 52 min and the stationary phase pumped
at 10 ml/min until 75 min. The procedure was repeated 15 times processing 450 mg NPF in
total. The fractions collected were pooled into 3 main fractions, F1-F3, based on clustering of
peaks observed on a chromatogram for the separation of the NPF constructed using maximum
absorbance between 210 nm and 400 nm (S2 Fig). Fractions F1-F3 were rotary evaporated
under vacuum at 40°C, frozen and freeze-dried, where after they were stored at room tempera-
ture under vacuum in a desiccator in the dark.
Evaluation of estrogenic activity
Cell culture. HEK293 human embryonic kidney cells [50] (a kind gift from A. Swart, Stel-
lenbosch University, ATCC cat# CRL-1573) and MCF-7BUS cells [51] (a kind gift from A.
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Soto, Tufts University, USA) were maintained in Dulbecco’s Modified Eagles’s Medium
(DMEM) [Sigma Aldrich] supplemented with 100 IU/ml penicillin and 100 μg/ml streptomy-
cin (Sigma Aldrich) and 10% fetal calf serum (FCS) or 5% heat inactivated FCS, [Highveld Bio-
logicals, South Africa], respectively. All cells were maintained at 37°C, 5% CO2 and 95%
relative humidity.
Promoter reporter studies. HEK293 cells were seeded at 4 x 106 cells per plate in sterile
cell-binding 10 cm plates (The Scientific Group, South Africa) with 1:1 DMEM:HamF12 (Life
Technologies, South Africa) containing 10% FCS, 100 IU/ml penicillin and 100 μg/ml strepto-
mycin, where after the cells were allowed to settle for 24 h. The cells were then rinsed with PBS
(Thermo Scientific, South Africa), pre-heated to 37°C, to remove the phenol red and the
medium changed to phenol red-free DMEM (Sigma-Aldrich) supplemented with 10% FCS,
100 IU/ml penicillin and 100 μg/ml streptomycin. The HEK293 cells were then transfected
with a total amount of 6150 ng of plasmid DNA using the FugeneXtreme transfection reagent
(Roche Applied Science, South Africa) according to the manufacturer’s instructions. Cells were
transfected with an ERE containing promoter reporter construct (ERE.vit2.luc [52], a kind gift
from K. Korach, National Institute of Environmental Health Science, USA) and either estrogen
receptor (ER)α (pSG5-hERα [53],) or ERβ (pSG5-hERβ [52], gifts from F. Gannon, European
Molecular Biology Laboratory, Heidelberg, Germany. For cells transfected with ERα, 150 ng
pSG5-hERα, 3750 ng ERE.vit2.luc, and 2250 ng empty vector (pGL2-Basic, Promega, USA)
were used, while for cells transfected with ERβ 150 ng pSG5-hERβ, 3000 ng ERE.vit2.luc, and
3000 ng empty vector were used.
After 24 h the cells were replated into sterile 24-well cell-binding tissue culture plates
(Whitehead Scientific (Pty) Ltd, South Africa) at 5 x 104 cells per well using phenol red-free
DMEM supplemented with 10% charcoal stripped FCS (Highveld Biologicals), 100 IU/ml peni-
cillin and 100 μg/ml streptomycin. The following day the cells were treated with the respective
test compounds or samples (extracts or fractions), all dissolved in DMSO to yield a final
DMSO concentration of 0.1% (v/v) in the medium. All extracts and fractions were tested at a
concentration of 9.8 μg/mL [31].
The samples and test compounds were tested in both agonist and antagonist (in the presence
of 10−11 M E2) mode, with DMSO serving as the solvent control, and E2, the endogenous ligand
of the ER, serving as the positive control. After 24 h the cells were rinsed using 500 μL ice cold
PBS and lysed overnight at -20°C using 50 μL passive lysis buffer [0.2% (vol/vol) Triton, 10%
(vol/vol) glycerol, 2.8% (vol/vol) Tris-phosphate-EDTA, and 1.44 mM EDTA]. Luciferase assays
were performed using the Luciferase assay reagent (Promega, USA) according to manufacturer’s
instruction, where 50 μL of luciferase reagent was added to 10 μL of cell lysate. The luciferase
activity, given in relative light units (RLUs), was obtained using a Veritas luminometer (Turner
Biosystems, USA). Protein determination was done using the Bradford method [54], where
250 μL of the Bradford reagent was added to 5 μL of the cell lysate in a 96-well plate. Luciferase
RLUs were normalised to protein concentration and the results were expressed as fold-induc-
tion relative to DMSO, which was set as one, for agonist mode, whereas, for antagonist mode
the results were expressed as fold-induction relative to 10−11 M E2, which was set as one.
Proliferation studies. MCF-7 BUS cells, which had been withdrawn from the penicillin-
streptomycin mixture for at least 7 days, were plated at a density of 1 x 104 cells per well in a
96-well plate (Greiner Bio-One, Germany) in DMEM containing 5% FCS. The next day the cells
were washed with PBS (200 μL/well), pre-heated to 37°C, and the medium was changed to
unsupplemented phenol red-free DMEM (200 μL/well) for 24 h (steroid and growth factor star-
vation), after which the medium was aspirated and cells incubated for a further 24 h with the
test compounds and extracts (in DMSO) in phenol red-free DMEM containing 10% stripped
FCS. The medium was then aspirated and cells re-induced at 24 and 48 h after initial treatment.
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All assays included a negative control consisting of 0.1% (v/v) DMSO and a positive control
(10−9 M E2). The MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] (Sigma
Aldrich) assay was performed 24 h after the last treatment, where medium was aspirated and
cells incubated with unsupplemented phenol red-free medium (200 μL/well) plus MTT solution
(5 mg/mL; 50 μL/well) for 4 h at 37°C. After the 4 h incubation, the wells were aspirated and
DMSO (solubilisation solution; 200 μL/well) was added. The DMSO was then pipetted up and
down twice per well in order to obtain a uniform purple colour in each well. The absorbance
value of each well was measured at 550 nm using a BioTek PowerWave 340 spectrophotometer
(Biotek instruments, USA). Results were expressed as fold induction relative to the solvent con-
trol (DMSO) for agonism or relative to 10-9M E2 for antagonism, which was set as one. For
investigation in agonist mode test samples were administered alone, whereas for investigation in
antagonist mode, test samples were administered in the presence of 10-9M E2.
Characterization of phenolic content
Quantification of phenolic compounds using qHPLC. Stock solutions of standards,
SM6Met and fractions, were prepared in DMSO and frozen at -20°C until needed for analysis.
For experimental analysis, the defrosted extract, fractions and standards were appropriately
diluted with water and ascorbic acid (Sigma Aldrich) was added to a final concentration of ca 9
mg/mL. The mixtures were then filtered using Millex-HV syringe filters (Millipore, USA) with
a 0.22 μm pore size. Separation was achieved on a Gemini-NX C18 column (150 × 4.6 mm;
3 μm; 110 Å; Phenomenex, USA), protected by a guard column (4 x 3.0 mm; Phenomenex) of
the same stationary phase, with 2% aqueous acetic acid (A, Sigma Aldrich) and HPLC gradi-
ent-grade acetonitrile (B, Sigma Aldrich) as mobile phases. Injection volumes ranged from 10–
20 μL for standards and 15 μL for the extract and fractions. Separation was performed using
the HPLC method described by De Beer et al. [55]. A flow rate of 1 mL/min was used with the
following mobile phase gradient: 0–2 min (8% B), 2–27 min (8–38% B), 27–28 min (38–50%
B), 28–29 min (50% B), 29–30 min (50–8% B), 30–40 min (8% B).
The dihydrochalcones (phloretin-3',5'-di-C-β-D-glucoside and 3-hydroxyphloretin-3',5'-di-
C-hexoside), flavanones (eriocitrin and hesperidin), benzophenones (iriflophenone-3-C-β-D-
glucoside and iriflophenone-3-C-β-D-glucoside-4-O-β-D-glucoside) and benzoic acid (proto-
catechuic acid) were quantified at 288 nm, whereas the xanthones (mangiferin and isomangi-
ferin), flavones (luteolin and scolymoside) and hydroxycinnamic acid (p-coumaric acid) were
quantified at 320 nm. A 7-point calibration curve was set up for all the available standards:
luteolin, mangiferin, isomangiferin, eriocitrin, hesperidin, vicenin-2, iriflophenone-3-C-β-D-
glucoside-4-O-β-D-glucoside, iriflophenone-3-C-β-D-glucoside, scolymoside, phloretin-3',5'-
di-C-β-D-glucoside, protocatechuic acid and p-coumaric acid. 3-Hydroxyphloretin-3',5'-di-C-
hexoside were expressed in terms of phloretin-3',5'-di-C-β-D-glucoside equivalents as no
authentic reference standard was available.
Identification of phenolic compounds using LC-MS/MS analysis. Analyses were per-
formed on a Waters Acquity ultra-performance liquid chromatography (UPLC) system com-
prising an in-line degasser, diode array detector (DAD), column oven and binary pump. This
system was coupled to a Synapt G2 quadrupole time of flight (QTOF) mass spectrometer
(Waters) containing an electrospray ionization (ESI) source. The method used was the same as
described in De Beer et al. [55] for LC-MS/MS analysis. An injection volume of 10 μL was used
for samples with the eluent being split 1:1 before introduction to the ionization source. MS
results were acquired in the negative ionization mode with MS and MSE for each sample. For
MSE a collision energy ramp from 25 to 60 V was used, whereas for MS/MS data a collision
energy of 30 V was used. The parameters used for MS were as follows: capillary voltage, 2.5 kV,
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cone voltage 15 V, desolvation temperature 275°C, source temperature 120°C and nitrogen
flow rate 650 L/h. Peaks were identified by comparing LC-MS spectra, UV-Vis spectra and
retention times to authentic reference standards or as in De Beer et al. [55]. Data were acquired
and processed by means of MassLynx v4.1 software (Waters).
Data manipulation and statistical analysis
GraphPad Prism version 5 (GraphPad Software, USA) was used for graphical representation
and statistical analysis of experimental data. One-way analysis of variance (ANOVA) was per-
formed with Dunnett’s multiple comparisons test as post-test. For all experiments, unless oth-
erwise indicated, the error bars represent the SEM (standard error of means) of three
independent experiments done in triplicate.
Results
The desirable estrogenic attributes previously identified [31,32] were used as the basis for the
activity-guided fractionation of SM6Met. Specifically, ERα antagonism and ERβ agonism activ-
ity were evaluated in the HEK293 cell line (does not contain endogenous ERα or ERβ (S3A
Fig) transfected with an ERE-containing promoter reporter construct and expression vectors
for either ERα or ERβ. In addition, antagonism of E2-induced breast cancer cell proliferation
was investigated in MCF-7 BUS cells, which endogenously express both ERα and ERβ (Fig B in
S3 Fig), and is a more complex and physiologically relevant model. Furthermore, LC-MS and
qHPLC were used to track major polyphenols during fractionation to allow for correlation
with estrogenic activity in an attempt to identify possible marker compounds.
To assist the reader we provide an overview of the fractionation process and yields obtained
(S1 Fig). Initially, the M6 harvesting of C. subternata was used to produce SM6Met, which was
subsequently fractionated into the PF and the NPF using liquid-liquid fractionation. The NPF
was sub-fractionated via HPCCC yielding F1-F3. The qHPLC chromatograms of SM6Met (Fig
1A), the NPF (Fig 1B) and F3 (Fig 1C), with their respective major polyphenolic constituents,
are shown in Fig 1.
Liquid-liquid fractionation of SM6Met to obtain a polar fraction (PF) and a
non-polar fraction (NPF)
SM6Met (4.30 g), displaying the three desirable estrogenic traits of interest [31,32], was frac-
tionated, according to relative polarity by means of liquid-liquid fractionation (S1 Fig), into
two fractions, the PF (2.92 g) and the NPF (1.21 g), resulting in a total recovery of 96%.
Constituent analyses indicate that the major compounds in SM6Met are retained and
concentrated in the NPF. LC-MS/MS analysis was used as a sensitive technique to identify
compounds present in SM6Met (S1 Table, Fig A in S4 Fig). Most of the identified compounds
had previously been identified in aqueous C. subternata extracts [55] or isolated from C. subter-
natamethanol extracts [56]. However, some new compounds present at low concentrations
were tentatively identified namely, luteolin-O-hexoside, chrysoeriol-O-deoxyhexose-O-hexo-
side (flavone), and quercetin-O-deoxyhexose-O-hexoside (flavonol).
The major phenolic compounds in SM6Met identified by LC-MS/MS (S1 Table), i.e. iriflo-
phenone-3-C-β-D-glucoside, mangiferin, isomangiferin, scolymoside, hesperidin, eriocitrin,
phloretin-3',5'-di-C-β-D-glucoside, and 3-hydroxyphloretin-3',5'-di-C-hexoside, as well as the
phenolic acid, protocatechuic acid, were quantified by qHPLC (Fig 1A, Table 1). p-Coumaric
acid was identified, but could not be accurately quantified due to co-elution. In addition, luteo-
lin, a minor compound, was also quantified as previous studies had shown that the presence of
luteolin might correlate with estrogenic activity of Cyclopia extracts [30,31]. Furthermore, two
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Fig 1. Identification of the major phenolic constituents in SM6Met, the NPF, and F3. qHPLC
chromatograms of (A) SM6Met, (B) the NPF, and (C) F3. The first peak in all samples represents ascorbic
acid (not numbered), which was added to prevent oxidation. Peak 1 = iriflophenone-3-C-β-D-glucoside-4-O-
β-D-glucoside; 2 = protocatechuic acid; 3 = iriflophenone-3-C-β-D-glucoside; 4 = mangiferin;
5 = isomangiferin; 6 = vicenin-2; 7 = p-coumaric acid; 8 = 3-hydroxyphloretin-3',5'-di-C-hexoside;9 = eriocitrin;
10 = scolymoside; 11 = phloretin-3',5'-di-C-β-D-glucoside; 12 = hesperidin; 13 = luteolin.
doi:10.1371/journal.pone.0132950.g001
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other minor compounds in SM6Met, iriflophenone-3-C-β-D-glucoside-4-O-β-D-glucoside
and vicenin-2, were included as they could be quantified.
The flavanones, hesperidin and eriocitrin, the flavones, scolymoside and luteolin, and the
dihydrochalcones, 3-hydroxyphloretin-3',5'-di-C-hexoside and phloretin-3',5'-di-C-β-D-gluco-
side, comprised approximately 24% each of the quantified major compounds. The xanthones,
mangiferin and isomangiferin, constituted 21% of the quantified major compounds. Further-
more, the benzophenone, iriflophenone-3-C-β-D-glucoside, comprised only 4.8% of the quan-
tified major compounds, while the phenolic acids, p-coumaric acid and protocatechuic acid,
were only present in trace amounts.
LC-MS/MS results (S1 Table, S4B and S4C Fig) showed that all of the major compounds in
SM6Met were retained as major compounds in the NPF, whereas for the PF most of these major
compounds, with the exception of 3-hydroxyphloretin-3',5'-di-C-hexoside, scolymoside, phlore-
tin-3',5'-di-C-β-D-glucoside, and hesperidin, were now present as minor compounds. In addition,
qHPLC analysis (Table 1) of the NPF, when compared to SM6Met, showed an overall 2- to 3-fold
increase in the concentration factor of the major compounds, while a 3- to 20-fold decrease was




















4d Mangiferin 1.90 1.00 100 0.09 0.05 3.22 5.56 2.93 82.35
5 Isomangiferin 0.65 1.00 100 0.05 0.08 5.22 1.88 2.91 81.39
6 Vicenin-2 (apigenin-6,8-di-C-
β-D-glucoside)
0.19 1.00 100 0.10 0.53 35.74 0.37 1.95 54.80
10 Scolymoside (luteolin-7-O-
rutinoside)
2.87 1.00 100 0.24 0.08 5.68 8.25 2.88 80.89
13 Luteolin 0.04 1.00 100 Nde Nd 0.00 0.11 2.63 77.39
1 Iriﬂophenone-3-C-β-D-
glucoside-4-O-β-D-glucoside
0.88 1.00 100 1.02 1.16 78.70 0.60 0.68 19.19
3 Iriﬂophenone-3-C-β-D-
glucoside
0.58 1.00 100 0.20 0.34 23.41 1.36 2.34 65.98
8 3-Hydroxy-phloretin-3',5'-di-
C-hexoside
1.16 1.00 100 0.38 0.32 22.24 2.79 2.41 67.68
11 Phloretin-3',5'-di-C-β-D-
glucoside
1.77 1.00 100 0.35 0.20 13.43 4.79 2.70 76.15
9 Eriocitrin (eriodictyol-7-O-
rutinoside)
0.85 1.00 100 0.19 0.22 15.18 2.13 2.52 70.52
12 Hesperidin (hesperetin-7-O-
rutinoside)
2.05 1.00 100 0.37 0.18 12.26 5.36 2.61 73.58
7 p-Coumaric acid co-elf 1.00 co-el Nd Nd 0.00 co-el co-el co-el
2 Protocatechuic acid 0.11 1.00 100 Nd Nd 0.00 0.35 3.07 89.54
ag/100 g refers to the amount of the compound present (g) in 100 g extract/fraction.
bConcentration factor refers to the amount of a compound in an extract or fraction divided by the amount of the compound in SM6Met. For example, for
mangiferin in the PF the concentration factor is (0.09 g/1.90 g) = 0.05.
cYield was calculated relative to the initial concentration of a compound in SM6Met, which was set to 100%. For example, for mangiferin in the PF, the
yield is (0.061 g/1.90 g) x 100 = 3.22%, where 0.061 g (0.09 g x 67.9 g/100 g) refers to the total amount of mangiferin present in the PF as only 67.9 g of
the PF is obtained during fractionation of 100 g SM6Met (as illustrated in S1 Fig).
dRefers to peak number in qHPLC chromatogram in Fig 1.
eNd—polyphenols were not detected due to absence or trace amounts.
fco-el—Co-elution refers to the fact that p-coumaric acid co-elutes with 3-hydroxyphloretin-3',5'-di-C-hexoside.
doi:10.1371/journal.pone.0132950.t001
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observed in the PF. In terms of the overall yield of the quantified compounds, relative to SM6Met
(set as 100%), values ranged from 66–90% for the NPF and 0.0–23% for the PF (Table 1).
Further analysis of the NPF (Table 1) showed that the xanthones, flavones, flavanones and
dihydrochalcones each contributed 23–26% towards the quantified compounds, whereas the
benzophenone, iriflophenone-3-C-β-D-glucoside, and the phenolic acid, protocatechuic acid,
contributed 4.2 and 1.1%, respectively. Thus, as a percentage of the quantified compounds the
xanthones, flavones, and protocatechuic acid slightly increased, while iriflophenone-3-C-β-D-
glucoside, flavanones, and dihydrochalcones slightly decreased in the NPF relative to SM6Met.
In contrast, although in much lower quantities, the PF consisted mostly of the dihydrochal-
cones, 3-hydroxyphloretin-3',5'-di-C-hexoside, and phloretin-3',5'-di-C-β-D-glucoside
(39.0%), and the flavanones (30.0%), followed by the flavone, scolymoside (12.8%), the benzo-
phenone, iriflophenone-3-C-β-D-glucoside (10.7%), and low amounts of the xanthones (7.5%).
In conclusion, constituent analysis using qHPLC indicates that liquid-liquid fractionation
of SM6Met results in retention and concentration (2- to 3-fold) of the major compounds in the
NPF.
Estrogenic activity analyses indicate that the desirable estrogenic attributes of SM6Met
are retained in the NPF. One of the three desirable estrogenic attributes of SM6Met previ-
ously demonstrated in COS-1 cells [32], namely ERα antagonism, was also demonstrated in
HEK293 cells (Fig 2C), however, in contrast to previous results, significant agonism via ERα
was also shown in HEK293 cells (Fig 2A). This conflict with previous results may be explained
by the fact that the HEK293 cells displayed a greater estrogenic sensitivity than the COS-1 cells
[32], as demonstrated by the differences in response to E2. However, SM6Met-induced ERα
agonism was significantly lower than that of 10-11M E2 (Fig 2A). Both the PF and the NPF
retained significant ERα antagonist activity (Fig 2C), one of the positive estrogenic attributes of
interest. In addition, in contrast to SM6Met, which displayed significant ERα agonism (Fig
2A), neither the PF nor the NPF showed significant agonism via ERα (Fig 2A). The absence of
ERα agonism, as seen for the PF and the NPF, positions them more favorably in terms of posi-
tive estrogenic attributes compared to the original SM6Met as ERα agonism is known to be
pro-proliferative [42].
The second desired positive estrogenic attribute we investigated was ERβ agonism. SM6Met
showed significant ERβ agonism (Fig 2B), which was also significantly higher than that of 10-
11M E2. These results suggest that SM6Met is a stronger ERβ agonist than an ERα agonist. Fur-
thermore, SM6Met did not display ERβ antagonism (Fig 2D). ERβ agonism was retained by
the NPF, however, the PF displayed no significant ERβ agonism. In addition, no ERβ antago-
nism was seen for either fraction (Fig 2D).
The third and final positive estrogenic attribute investigated was antagonism of E2-induced
breast cancer cell proliferation in MCF-7 BUS cells. As previously demonstrated [32], SM6Met
showed significant antagonism (Fig 2F) of E2-induced breast cancer cell proliferation. In addi-
tion, it did not induce breast cancer cell proliferation in agonist mode (Fig 2E). Furthermore,
significant antagonism of E2-induced breast cancer cell proliferation was retained by both the
PF and the NPF (Fig 2F). In addition, like SM6Met, PF and NPF did not induce significant
breast cancer cell proliferation in agonist mode (Fig 2E).
Thus in summary, the NPF retained all of the positive estrogenic attributes previously
described for SM6Met, namely, ERα antagonism, ERβ agonism and antagonism of E2-induced
breast cancer cell proliferation, whereas PF retained only ERα antagonism and antagonism of
E2-induced breast cancer cell proliferation, but not ERβ agonism. As ERβ agonism is consid-
ered an important positive estrogenic attribute for the development of a possible phytoestro-
genic nutraceutical, due to its anti-proliferative function [42], we decided to focus on NPF,
rather than PF, for subsequent fractionation.
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Fig 2. The NPF retains all three desirable estrogenic attributes of SM6Met. To establish retention of the desirable estrogenic attributes of SM6Met,
promoter reporter and proliferation studies were conducted using E2 (positive control), SM6Met, the NPF, and the PF. Promoter reporter studies in HEK293
cells transfected with ERE.vit2.luc and either pSG5-hERα (A&C) or pSG5-hERβ (B&D) were conducted in agonist (A&B) and antagonist (C&D) mode.
Proliferation studies using MCF-7 BUS cells were conducted in agonist (E) and antagonist (F) mode. Statistical analysis was done using One-way ANOVA
with Dunnett’s post-test comparing all columns to either solvent control (black bar) (*, P<0.05; **, P<0.01;***, P<0.001) or E2 (grey bar) (#, P<0.05; ##,
P<0.01; ###, P<0.001). The dotted lines through the bars represent the values for solvent control and/or E2 used for statistical analysis.
doi:10.1371/journal.pone.0132950.g002
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Fractionation of the NPF by HPCCC to obtain F1-F3
As the NPF retained all of the positive estrogenic attributes of interest, it was fractionated fur-
ther using HPCCC, which yielded three major fractions (F1, F2 and F3), with 0.45 g of the NPF
resulting in 0.180 g F1, 0.043 g F2 and 0.147 g F3 (S1 and S2 Figs). The overall yield of these
three HPCCC fractions was 82.2%.
Constituent analysis indicates that HPCCC fractionation of the NPF results in the diver-
gence of the major phenolic compounds across F1, F2, and F3. LC-MS/MS analysis of the
three HPCCC fractions (S1 Table, Fig D–F in S4 Fig) revealed that each HPCCC fraction had a
different compound profile, which was also different from that of the NPF. In addition,
qHPLC analysis of the HPCCC fractions (Table 2, Fig 1C) revealed that F1 consisted mainly of
dihydrochalcones (90% of quantified compounds in F1) and retained most (97%) of the dihy-
drochalcones recovered during HPCCC (Table 2). Of the dihydrochalcones in F1, phloretin-
3',5'-di-C-β-D-glucoside was concentrated approximately 5-fold and 2-fold relative to SM6Met
and the NPF, respectively, while 3-hydroxyphloretin-3',5'-di-C-hexoside was concentrated




















4d Mangiferin Nde Nd 0.00 Nd Nd 0.00 11.57 6.09 55.96
5 Isomangiferin Nd Nd 0.00 Nd Nd 0.00 4.02 6.18 56.84
6 Vicenin-2 (apigenin-6,8-di-
C-β-D-glucoside)
0.65 3.42 38.52 Nd Nd 0.00 Nd Nd 0.00
10 Scolymoside (luteolin-7-O-
rutinoside)
Nd Nd 0.00 Nd Nd 0.00 17.05 5.94 54.60




1.16 1.32 14.84 Nd Nd 0.00 Nd Nd 0.00
3 Iriﬂophenone-3-C-β-D-
glucoside
Nd Nd 0.00 10.28 17.72 47.68 0.08 0.14 1.27
8 3-Hydroxy-phloretin-3',5'-di-
C-hexoside
2.78 2.40 26.99 0.40 0.34 0.93 Nd Nd 0.00
11 Phloretin-3',5'-di-C-β-D-
glucoside
8.42 4.76 53.56 0.96 0.54 1.46 Nd Nd 0.00
9 Eriocitrin (eriodictyol-7-O-
rutinoside)
1.19 1.40 15.76 11.15 13.12 35.29 Nd Nd 0.00
12 Hesperidin (hesperetin-7-O-
rutinoside)
0.08 0.04 0.44 39.45 19.24 51.77 Nd Nd 0.00
7 p-Coumaric acid Nd Nd 0.00 Nd Nd 0.0 0.57 co-elf co-el
2 Protocatechuic acid Nd Nd 0.00 Nd Nd 0.0 0.65 5.91 54.30
ag/100 g refers to the amount of the compound present (g) in 100 g extract/fraction.
bConcentration factor refers to the amount of a compound in a extract or fraction divided by the content of the compound in SM6Met for example
mangiferin in F3 (11.57 g/1.90 g) = 6.09.
cYield was calculated relative to the initial concentration of a compound in SM6Met, which was set to 100%. For example, for mangiferin in F3, the yield is
(1.063 g/1.90 g) x 100 g = 55.96%, where 1.063 g (11.57 g x 9.19 g/100 g) refers to the total amount of mangiferin present in F3 as only 9.19 g of F3 is
obtained during fractionation of 100 g SM6Met (as illustrated in S1 Fig).
dRefers to peak number in qHPLC chromatogram in Fig 1.
eNd—polyphenols were not detected due to absence or trace amounts
fCo-elution refers to the fact that p-coumaric acid co-elutes with 3-hydroxyphloretin-3',5'-di-C-hexoside where present.
doi:10.1371/journal.pone.0132950.t002
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approximately 2-fold relative to SM6Met, but not concentrated relative to the NPF (Tables 1
and 2). F1 also contained a minor flavanone component (10% of quantified compounds in F1)
consisting mostly of eriocitrin.
In contrast to F1, F2 retained 91% of all flavanones recovered during HPCCC (Table 2)
and consisted mostly of the flavanones (81% of quantified compounds in F2). Of the flava-
nones in F2, eriocitrin was concentrated approximately 13-fold and 5-fold relative to SM6Met
and the NPF, respectively, while hesperidin was concentrated approximately 19-fold and
7-fold relative to SM6Met and the NPF, respectively (Tables 1 and 2). Although the benzophe-
none, iriflophenone-3-C-β-D-glucoside, only constituted approximately 16% of the quantified
compounds in F2 it represented 97% of the benzophenones recovered during HPCCC and
was concentrated approximately 18-fold and 8-fold relative to SM6Met and the NPF, respec-
tively (Tables 1 and 2). F2 also contained a minor dihydrochalcone component (2% of quanti-
fied compounds in F2).
All the xanthones, flavones and phenolic acids eluted in F3 so that this fraction consisted of
approximately 46% xanthones, 51% flavones and 4% phenolic acids (Table 2). Only trace
amounts of the benzophenone, iriflophenone-3-C-β-D-glucoside, were present in F3. The xan-
thone component of F3 was concentrated approximately 6-fold and 2-fold relative to SM6Met
and the NPF, respectively, while the flavones were concentrated approximately 5- to 6-fold and
2- to 3-fold relative to SM6Met and the NPF, respectively (Tables 1 and 2).
In terms of the overall yields of the quantified compounds, with respect to SM6Met (set as
100%), the dihydrochalcones in F1 values ranged from 27 to 54%, the flavanones in F2 values
ranged from 35% to 52%, while the xanthones and flavones in F3 values ranged from 48% to
57% (Table 2).
To conclude, constituent analysis using qHPLC indicates that HPCCC fractionation of the
NPF resulted in a dihydrochalcone-rich fraction (F1), a benzophenone- and flavanone-rich
fraction (F2), and a xanthone- and flavone-rich fraction (F3). Thus, HPCCC fractionation
resulted in the divergence of the type of phenolic compounds present in the NPF.
Estrogenic activity analysis reaffirms the divergence observed during constituent analy-
sis in that the desirable estrogenic attributes of the NPF were also separated. In accordance
with the activity of the NPF, F1 and F2 displayed significant ERα antagonism, however, F3 dis-
played no ERα antagonism (Fig 3C). In addition, only F3 displayed significant ERα agonism
(Fig 3A), though, it was weak and significantly lower than that of 10−11 M E2, reflecting an
“activity profile” quite similar to that of SM6Met (Fig 2A).
Investigation of HPCCC fractions for ERβ agonism revealed that F3 acted as a very potent
ERβ agonist, eliciting a 4.5-fold induction (Fig 3B). In contrast, F1 and F2 showed no signifi-
cant ERβ activation. In addition, only F1 displayed significant ERβ antagonism (Fig 3D).
Similar to the NPF, none of the HPCCC fractions, with the exception of F3, induced signifi-
cant breast cancer cell proliferation (Fig 3E). Furthermore, only F2, like the NPF, displayed sig-
nificant antagonism of E2-induced breast cancer cell proliferation (Fig 3F).
Thus, in summary, analysis of the HPCCC fractions revealed divergence of the previously
demonstrated positive estrogenic attributes of the NPF into separate fractions, with F1 and F2
retaining ERα antagonism, only F2 retaining antagonism of E2 induced breast cancer cell pro-
liferation, and only F3 retaining ERβ agonist activity. ERβ agonism was the only desirable
estrogenic attribute of the NPF augmented by HPCCC fractionation in that F3 induction via
ERβ was significantly higher than that obtained with the NPF (statistics not shown). In addi-
tion, the ERβ agonism displayed by F3 was very robust in being significantly higher than that
of 10−11 M E2 and comparable to that of 10
−9 M E2 (4.5-fold vs. 5.4-fold). Furthermore, as ERβ
agonists have recently come to the fore as strong alternative candidates for the treatment of
breast cancer [40,57,58], F3 was chosen to be re-engineered [48].
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Fig 3. The three desirable estrogenic attributes of the NPF are not retained in one fraction after CCC fractionation. To establish retention of the
desirable estrogenic attributes of the NPF, promoter reporter and proliferation studies were conducted using E2 (positive control), the NPF, F1, F2, and F3.
Promoter reporter studies in HEK293 cells transfected with ERE.vit2.luc and either pSG5-hERα (A&C) or pSG5-hERβ (B&D) were conducted in agonist
(A&B) and antagonist (C&D) mode. Proliferation studies using MCF-7 BUS cells were conducted in agonist (E) and antagonist (F) mode. Statistical analysis
was done using One-way ANOVA with Dunnett’s post-test comparing all columns to either solvent control (black bar) (*, P<0.05; **, P<0.01;***, P<0.001)
or E2 (grey bar) (#, P<0.05; ##, P<0.01; ###, P<0.001). The dotted lines through the bars represent the values for solvent control and/or E2 used for statistical
analysis.
doi:10.1371/journal.pone.0132950.g003
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Reengineering of F3 with pure compounds (F3R) did not replicate ERβ
agonist activity
It has been suggested that one of the best strategies for verifying the pharmacological contribu-
tion of individual compounds towards the activity of a mixture would be to reengineer the mix-
ture using the compounds identified in the mixture [48]. Therefore, as quantitative data
regarding several compounds in F3 was available (Table 2), the F3 fraction could be re-engi-
neered as F3R using authentic reference standards of purity> 95%. F3R contained all the
major identifiable compounds (S1 Table, Fig F in S4 Fig) plus two commercially available
minor compounds that could be quantified (Table 2 and S1 Table, Fig F in S4 Fig) at the indi-
vidual concentrations of these compounds in a 9.8 μg/ml solution of F3.
F3 previously showed potent ERβ agonist activity (Fig 3B), which was also displayed upon
re-investigation (Fig 4), however, F3R displayed no ERβ agonist activity. Furthermore, evalua-
tion of the ERβ agonist activity of each individual compound at the concentration present in
9.8 μg/ml F3 also displayed no ERβ agonist activity.
Together these results indicate that the desired ERβ agonist activity of F3 could not be repli-
cated by reengineering F3 with the available compounds (Table 2). This suggests that other
compounds present in F3 may contribute to the robust ERβ activity of F3 (Fig F in S4 Fig).
Discussion
Activity-guided fractionation is commonly used to identify compounds within mixtures
responsible for specific activity profiles [57,59,60]. In the field of estrogenic nutraceuticals,
activity-guided fractionation was most successfully employed to isolate the ERβ-subtype spe-
cific agonist, liquiritigenin, from MF101, a plant extract containing 22 herbs, which has ERβ
selective properties [57]. In the case of SM6Met the desired positive estrogenic attributes are
more complex in that ERβ agonism, ERα antagonism and antagonism of E2-induced breast
cancer cell proliferation were simultaneously targeted. The existence of a compound displaying
more than one desired estrogenic attribute seemed possible as the R,R enantiomer of 5,11-cis-
diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (R,R-THC) has been shown to be both an ERα
agonist and an ERβ antagonist [61–63].
Our results from liquid-liquid fractionation of SM6Met into the PF and the NPF seemed
promising as indeed the three desirable estrogenic attributes were retained in the NPF (S2
Table). However, evaluation of the HPCCC fractions (F1, F2, F3) obtained from the NPF sug-
gested that it is unlikely that the three desirable estrogenic attributes of SM6Met can be
ascribed to a single compound. Specifically, it was shown that ERβ agonism was only observed
for F3, ERα antagonism was only observed for F1 and F2, while antagonism of E2-induced
breast cancer cell proliferation was only observed for F2 (S2 Table). Of note, ERβ agonism was
significantly augmented during the fractionation process so that F3 displayed an approximately
2-fold increase in ERβ agonism relative to the starting material, SM6Met (S2 Table). Remark-
ably, the ERβ agonism of F3 was 260% more than that obtained with 10−11 M E2 and only 17%
less than that obtained with 10−9 M E2.
The divergence of the three desirable estrogenic attributes observed during HPCCC frac-
tionation may be ascribed to the separation of the major compounds into the individual
HPCCC fractions. Specifically, F1 consisted mainly of the dihydrochalcones, F2 mainly of the
flavanones and the benzophenone, and F3 mainly of the xanthones, the flavones, and the phe-
nolic acids. In terms of identifying polyphenol marker compounds contributing to the estro-
genic activity of F3, the fraction displaying robust ERβ agonism, it is unlikely that mangiferin
or p-coumaric acid directly contributed as they lack estrogenic activity [29,30,64,65]. The other
major xanthone present in F3, isomangiferin, has, to our knowledge, not been tested for
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estrogenic activity, nor has the flavone, scolymoside, or the phenolic acid, protocatechuic acid
[33]. Thus, the flavone, luteolin, is the only compound in F3 that could have contributed to the
estrogenic activity. Luteolin has been shown to bind to the ERs, to elicit an estrogenic response
using an ERE-containing promoter reporter construct, to induce breast cancer cell prolifera-
tion, and to antagonize E2-induced breast cancer cell proliferation, however, unlike F3, luteolin
does not display a significant preference for ERβ signaling [29,30,66,67].
Since none of the major compounds in F3 independently appeared to be responsible for the
robust ERβ agonism observed, to evaluate their combined effect we re-engineered F3 using the
major quantifiable compounds (Table 2). However, neither the re-engineered F3 (F3R), nor the
individual compounds present in F3R elicited any ERβ agonism. Thus, two possibilities may
explain the robust ERβ agonism of F3: Firstly, the unidentified major compounds in F3 (Fig F in
S4 Fig, approximately 7.4, 20.0, and 20.5 minutes) may be the elusive ERβ agonist(s), or
Fig 4. Reengineering of F3 with pure compounds (F3R) does not replicate ERβ agonist activity. To replicate the desirable estrogenic attribute
displayed by F3, ERβ agonism, promoter reporter studies were conducted in HEK293 cells transfected with ERE.vit2.luc and pSG5-hERβ. Cells were
induced with 10−9 M E2, 9.8 μg/mL F3, 9.8μg/mL F3R (consisting of 1.13 μg mangiferin, 0.39 μg isomangiferin, 1.67 μg scolymoside, 0.02 μg luteolin, 0.01 μg
iriflophenone-3-C-glucoside, 0.06 μg p-coumaric acid, 0.06 μg protocatechuic acid as in 9.8 μg F3 (Table 2). Statistical analysis was done using One-way
ANOVA with Dunnett’s post-test comparing all columns to either solvent control (black bar) (*, P<0.05; **, P<0.01;***, P<0.001) or F3 (grey bar) (#, P<0.05;
##, P<0.01; ###, P<0.001). The dotted lines through the bars represent the values for solvent control or F3.
doi:10.1371/journal.pone.0132950.g004
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secondly, the minor compounds in F3 (S1 Table) may individually, although unlikely as they
are present in very low concentrations, or collectively contribute to the robust activity of F3.
In the field of nutraceutical development, the idea of intelligent mixtures in the investigation
of activity, induced by a mixture of compounds, has become increasingly popular [48,68–72]. A
mixture would allow for synergistic, additive or antagonistic effects to contribute to the desired
estrogenic traits in that the combination of a large number of weakly active compounds may
exert an effect without the necessity of the presence of one major highly active compound. For
example, it has recently been demonstrated by Bartoszewski et al. [73] that even though hesperi-
din has been shown to elicit cell growth arrest and apoptosis in various cancer cell lines includ-
ing pancreatic cancer cells, colon cells, and breast cancer cells [74–77], the presence of
mangiferin results in an additive apoptotic effect. Furthermore, Kumar et al. investigated the
synergistic effects of three phytoestrogens (genistein, quercetin and biochanin A) and found that
these phytoestrogens in combination had a more potent inhibitory effect on androgen-respon-
sive prostate cancer cell growth in vitro [21]. Synergismmay not only be applicable to one target,
such as the ER, but could also involve multiple targets. In fact, it has been suggested that in most
botanical drugs multi target effects may actually predominate over other synergistic mechanism
[78]. For example, it has been shown that a polyphenol-based matrix, due to the presence of spe-
cific polyphenols, can result in an increase [79] in the absorption of other polyphenols.
In summary, the current study illustrated that it is unlikely that one compound is responsi-
ble for the desired estrogenic attributes displayed by SM6Met, but rather that multiple com-
pounds contribute to the activity of the extract, either individually (additive), or by eliciting a
synergistic or antagonistic effect in the presence of other SM6Met compounds. Thus, the tradi-
tional paradigm in drug discovery of dividing a mixture, such as SM6Met, in the hope of dis-
covering a single highly active compound influencing an individual target, such as the ER, may
not be the optimal approach towards retaining the complex desirable estrogenic attributes of a
Cyclopia nutraceutical extract. The concept of intelligent mixtures may therefore be more rele-
vant to not only the robust ERβ agonism of F3, but also to the NPF, which displayed all three of
the pursued desirable estrogenic attributes.
Thus the current study could serve as a stepping stone in the possible future development of
not only a uniquely South African honeybush-derived oral phytoestrogenic nutraceutical but
may also be applicable to other studies of complex mixtures displaying desirable attributes that
are complex in encompassing more than one molecular target.
Supporting Information
S1 Fig. SM6Met production and fractionation scheme.M6 C.subternata harvesting was sub-
jected to sequential methanol extraction according to Mfenyana et al. [1]. The resultant
SM6Met was fractionated using liquid-liquid fractionation to yield the PF and the NPF, which
was subsequently fractionated into F1, F2, and F3 using HPCCC. Experimental details are
given in the Materials and Methods section. Yields are expressed as if 100 g SM6Met was used
in fractionation. Values in brackets represent the actual mass used during the study.
(TIF)
S2 Fig. Representative high performance counter-current chromatogram (HPCCC) of the
NPF. Specific fractions were pooled to form F1 (22–40 min), F2 (41–52 min) and F3 (52–75
min).
(TIF)
S3 Fig. Estrogen receptor characterization of the HEK293 and MCF-7 BUS cell lines.West-
ern blot analysis reveals (A) the absence of ERα and ERβ in the HEK293 cell line and the (B)
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presence of ERα and ERβ in the MCF-7 BUS cell line. The + Control represents lysates from
COS-1 cells transfected with the cognate receptor, while the—Control represents lysate from
untransfected COS-1 cells. Western blot analysis was performed as previously described [2].
(TIF)
S4 Fig. LC-MS/MS chromatograms of SM6Met and subsequent fractions obtained during
activity-guided fractionation. (A) SM6Met, (B) the NPF, (C) the PF, (D) F1, (E) F2, and (F)
F3. Chromatograms indicate base peak intensity (BPI) with the peak numbers corresponding
to the numbering in S1 Table. The initial peak in all samples corresponds to ascorbic acid (not
numbered), which was added to prevent oxidation. Peaks above the dotted lines were consid-
ered major peaks, whilst peaks below the dotted lines were considered minor peaks as indicated
in S1 Table.
(TIF)
S1 Table. LC-MS/MS data (S4 Fig) of compounds present in SM6Met and subsequent frac-
tions obtained during activity-guided fractionation.
(PDF)
S2 Table. Purification table of estrogenic activity.
(PDF)
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